{"id":"W4310595717","doi":"10.1007/s11523-022-00931-9","title":"Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Innovaderm (Canada)","funders":"Mirati Therapeutics","keywords":"Medicine; Nausea; Pharmacokinetics; Vomiting; Adverse effect; Internal medicine; Gastroenterology; Cancer; Response Evaluation Criteria in Solid Tumors; Capsule; Pharmacology; Chemotherapy; Progressive disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000208725,0.0001420056,0.0004246721,0.0001416337,0.000105649,0.00000405135,0.00004272607,0.00003245275,0.000135277],"category_scores_gemma":[0.00001875203,0.0001156409,0.00001528462,0.000195775,0.00005223292,0.00005781875,0.00007340485,0.0001591881,1.811752e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002824197,"about_ca_system_score_gemma":0.0004033885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005488279,"about_ca_topic_score_gemma":0.0003706998,"domain_scores_codex":[0.9988573,0.0001369488,0.0003051084,0.0003113261,0.0001875461,0.0002017799],"domain_scores_gemma":[0.9994079,0.00005688754,0.0002087801,0.0001429384,0.00008762399,0.00009579462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002602349,0.007667087,0.9345664,0.00008993834,0.0001890496,0.00003906879,0.01974802,0.0005206783,0.005130203,0.00000374161,0.00003405384,0.02940939],"study_design_scores_gemma":[0.1924106,0.1402149,0.6292018,0.0001603555,0.001777186,0.00001323491,0.02817238,0.004297727,0.00275914,0.00003471213,0.0004550222,0.0005028989],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971561,0.0004170589,0.000007213415,0.00004650976,0.00008750438,0.00186828,0.0001082408,0.0000147111,0.0002943382],"genre_scores_gemma":[0.9970857,0.000004298767,0.001969744,0.0002143389,0.00002744507,0.0005475041,0.00005633682,0.00002825602,0.0000663926],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3053646,"threshold_uncertainty_score":0.47157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01739782352627714,"score_gpt":0.3924252135381065,"score_spread":0.3750273900118293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}